Figure 2

Seroreactive response of patients with CIN 1 and HPV-16 infection to HPV16 E6 and E7 antigenic peptides contained in cVLPs. (A) The IgG antibody response in sera from donors without evidence of HPV infection (normal) and in sera from patients with CIN 1 and HPV-16 infection (HPV-16), against antigenic peptides derived from HPV-16 proteins was determined by ELISA. The HPV-16 peptides were: EIDGPAGQAEPDRAHYNI (E7 37-54), RAHYNIVTF (E7 49-57), PRKLPQLCTELQTTI (E6 16-30), and TLGIVCPI (E7 86-93). Additionally, the peptide MQYEIINYM T6/GS (338-346), derived from the polymerase accessory protein, was used as a negative control. The mean absorbance value of each group is represented by a solid line. (B) Shown are the mean absorbance distribution of the control positive group and the cut-off values for high seroreactivity at A 405 (indicated by horizontal dashed lines and numbers) in response to the seroreactive peptides E7 37-54 (gray circles), E7 49-57 (gray rhombus), E6 16-30 (gray squares), E7 86-93 (gray triangles). The seroreactivity to the irrelevant peptide T6/GS(338-346) (tails) is also depicted. *Indicates difference between groups is statistically significant. P-values were calculated using Wilcoxon signed-rank test and Student's t-test.